Related references
Note: Only part of the references are listed.Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia
Elizabeth A. Raetz et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2010)
Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia
J. C. Panetta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
FDA drug approval summary: Pegaspargase (Oncaspar (R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)
Patricia Anne Dinndorf et al.
ONCOLOGIST (2007)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Mast cell tryptase: a review of its physiology and clinical significance
V Payne et al.
ANAESTHESIA (2004)
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients
B Wang et al.
LEUKEMIA (2003)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
LB Silverman et al.
BLOOD (2001)
Share Paper
